| Annual · values | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -4.79 M USD | -5.20 M USD | -7.05 M USD | -7.46 M USD | -10.80 M USD | -8.68 M USD | -3.33 M USD | -1.93 M USD | -1.39 M USD | -157702 USD | -2.58 M USD | -1.74 M USD |
| Depreciation & Amortization | 618000 USD | 637000 USD | 657000 USD | 651000 USD | 478000 USD | 144000 USD | 59000 USD | 19414 USD | 396346 USD | 728741 USD | 781546 USD | 712314 USD |
| Stock-Based Compensation | 4.30 M USD | 4.60 M USD | 5.50 M USD | 7.00 M USD | 703000 USD | 521000 USD | 515000 USD | 576251 USD | 203200 USD | 214254 USD | 833127 USD | 181030 USD |
| Capital Expenditures | 112000 USD | 138000 USD | 310000 USD | 207000 USD | 1.47 M USD | 4.39 M USD | 15000 USD | 135731 USD | 145677 USD | 122185 USD | 76527 USD | 8485 USD |
| Cash Flow from Investing | -442000 USD | -317000 USD | -235000 USD | -742000 USD | 3.39 M USD | -9.55 M USD | -260000 USD | -657113 USD | -241354 USD | -183422 USD | -518088 USD | 3083 USD |
| Cash Flow from Financing | 4.45 M USD | 3.52 M USD | 100000 USD | 4.14 M USD | 14.69 M USD | -59000 USD | 27.60 M USD | 3.71 M USD | 707564 USD | 1.01 M USD | 2.90 M USD | 1.74 M USD |
| Dividends Paid | — | — | — | — | — | — | — | — | — | — | — | — |
| Stock Buybacks | — | — | — | — | — | — | — | — | — | — | — | — |
| Free Cash Flow | -4.91 M USD | -5.34 M USD | -7.36 M USD | -7.67 M USD | -12.27 M USD | -13.07 M USD | -3.35 M USD | -2.07 M USD | -1.54 M USD | -279887 USD | -2.66 M USD | -1.75 M USD |
IGC Pharma Inc. is a pharmaceutical and biotechnology company focused on the development and commercialization of innovative therapies for the treatment of chronic pain, cancer, and other life-altering conditions. The company's primary role involves leveraging unique approaches to drug development, particularly using cannabinoids, to create novel solutions that address unmet medical needs. IGC Pharma operates within the biotech sector, which is marked by significant research and development activities and a robust pipeline of products at various stages of clinical trials. Notably, IGC Pharma's initiatives in the pharmaceutical industry aim at integrating traditional pharmaceutical methods with new advancements in cannabinoid science. This positions the company as a potential influencer in sectors such as pain management and oncology, where treatment options are continually evolving. Due to its focus on strategic research and development, IGC Pharma plays a crucial role in the broader biotechnology market, aiming to introduce cutting-edge therapies that can change the standard of care for complex medical conditions.